| Q40960081 | A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma |
| Q27612411 | CIViC database |
| Q92781644 | Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis |
| Q64111945 | Establishment and molecular characterization of decitabine-resistant K562 cells |
| Q92946120 | HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma |
| Q92220417 | Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma? |
| Q37637537 | Identification of Predictive DNA Methylation Biomarkers for Chemotherapy Response in Colorectal Cancer |
| Q38772017 | Mutation analysis and gene expression profiling of ocular melanomas in cats. |
| Q90442747 | Roles of ERK1/2 and PI3K/AKT signaling pathways in mitochondria-mediated apoptosis in testes of hypothyroid rats |
| Q38798084 | Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives |
| Q33703068 | The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo |
| Q47321072 | Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors. |